Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
83.95%
Operating Margin
82.49%
Net Margin
34.46%
Efficiency Metrics
Revenue per Expense Ratio
5.71
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.2800000000
Balance Sheet Analysis
Current Ratio
5.64
Cash Ratio
4.22
Working Capital
$2.31M
Debt to Equity
0.66
Debt to Assets
39.59%
Equity Ratio
60.15%
Cash Flow Analysis
Operating Cash Flow Ratio
29.30%
Free Cash Flow Ratio
29.30%
CapEx to Revenue
0.00%
Dividends Paid
$3.39M
Stock Buybacks
No buybacks
Total Shareholder Returns
$3.39M
Cash Position Change
-95.60%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
310.87%
Net Income
169.63%
EPS
170.00%
Operating Income
6.73%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
761.90%
Operating Cash Flow
266.17%
Free Cash Flow
266.17%
Balance Sheet Health
Assets
-1.46%
Debt
0.04%
Book Value per Share
-1.85%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-11.61%
Shares Outstanding
1.02%
Long Term Trends
3Y Revenue/Share
-37.36%
5Y Revenue/Share
-17.47%
3Y Dividend/Share
-33.24%
5Y Dividend/Share
-28.98%